Summary & Overview
Local Excision and Removal of Internal Fixation Devices Except Hip and Femur with MCC: Inpatient Reimbursement Overview
DRG 495 encompasses local excision and removal of internal fixation devices except for hip and femur, when a Major Complication or Comorbidity is present; it covers higher-acuity inpatient orthopedic cases that require more resources. Correct classification matters for inpatient reimbursement because the Major Complication or Comorbidity status influences the Diagnosis-Related Group weight and resultant Medicare payment.
DRG 495 Overview
DRG 495 covers inpatient stays for local excision and removal of internal fixation devices, excluding procedures on the hip and femur, when a Major Complication or Comorbidity is present. Typical cases include removal of plates, screws, rods, or similar orthopedic hardware from extremities or the pelvis (excluding hip and femur) complicated by infection, significant bleeding, or other severe comorbid conditions. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity increases resource intensity and affects the inpatient reimbursement weight. Accurate coding of the principal procedure and the Major Complication or Comorbidity is therefore central to appropriate Medicare Severity Diagnosis-Related Group assignment and payment.
Clinical Trials
- Acute perioperative infection prevention studies: randomized or pragmatic trials evaluating surgical-site infection prevention bundles, antibiotic prophylaxis timing/duration, and wound-care protocols in patients undergoing local excision or removal of internal fixation devices (excluding hip and femur) who present with infected hardware or open wounds. These studies focus on the immediate preoperative and inpatient period in patients with implant-related infection, nonunion debridement, or soft-tissue compromise, measuring rates of persistent infection, need for reoperation, and length of stay. Results inform surgeons and hospital administrators about protocols that reduce complications and readmissions, directly affecting inpatient resource use and DRG-related costs.
- Comparative effectiveness research on fixation removal versus retention with local procedures for symptomatic hardware: observational cohort studies or registry-based comparative effectiveness analyses that examine functional outcomes, pain relief, complication rates, and subsequent procedures in patients who receive local excision and device removal versus those managed conservatively or with limited soft-tissue procedures. These studies target heterogeneous ambulatory and inpatient populations with painful, prominence-causing, or mechanically problematic hardware (non-hip/femur) and stratify by comorbidity burden and device type. Findings help clinicians select patients most likely to benefit from inpatient removal and help payers predict downstream utilization and justify appropriate DRG reimbursement for different care pathways.
- Post-discharge outcomes and care-transition trials: prospective studies or quality-improvement trials assessing discharge planning, home health coordination, pain management strategies, and physical-therapy initiation on 30- and 90-day outcomes such as readmission, wound complications, opioid use, and functional recovery after local excision or hardware removal. These trials enroll patients with higher acuity or medical complexity (MCC patients included in DRG 495) to evaluate interventions that reduce postacute complications and unplanned returns to care. Demonstrating reduced readmissions and improved recovery is relevant to clinicians and payers seeking to optimize length of stay, lower postdischarge costs, and align inpatient DRG payments with value-based outcomes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.